Deciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations

Marco Ranzani, Alessandro Cicconi, Guillermo Sastre-Moreno, Asmita Thapa, Elise Simon, Josefine Reber, Joseph Barlow, Marie Laure Boursier, Aurora Cerutti, Luisa Deberle, Luigi Del Pozzo, Elias Elinati, Lerin Geo, Vera Grinkevich, Charlene Hartnagel, Sravanth K. Hindupur, Katjusa Koler, Suraj Menon, Joana Neves, Barbara Schacher, Nan Shao, Eeson Rajendra, Markus Reschke, Tobias Schmelzle, Graeme C. M. Smith, Helen M. R. Robinson, Marta Cortes-Cros · 2026

Read Deciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations by Marco Ranzani, Alessandro Cicconi, Guillermo Sastre-Moreno, Asmita Thapa, Elise Simon, Josefine Reber, Joseph Barlow, Marie Laure Boursier, Aurora Cerutti, Luisa Deberle, Luigi Del Pozzo, Elias Elinati, Lerin Geo, Vera Grinkevich, Charlene Hartnagel, Sravanth K. Hindupur, Katjusa Koler, Suraj Menon, Joana Neves, Barbara Schacher, Nan Shao, Eeson Rajendra, Markus Reschke, Tobias Schmelzle, Graeme C. M. Smith, Helen M. R. Robinson, Marta Cortes-Cros (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13633323.txt.

Description

Marco Ranzani and colleagues published this 2026 study of how a radioactive cancer therapy damages tumors, hunting for drug partners that strengthen it. Radioligand therapy delivers a radioactive atom, lutetium-177, straight to cancer cells through targeting molecules. Cures remain rare, so better combinations are needed. The team profiled damage-response markers in treated cancer cell lines. They then tested cells missing various repair genes, alongside repair-blocking drugs, to find what makes cells most sensitive.

The treatment left clear signs of double-strand DNA breaks, the most dangerous kind of DNA damage. Cells that lost one repair route, called non-homologous end joining, became far more sensitive than any other group. Blocking that route's core enzyme, DNA-PK, strongly sensitized prostate cancer cells to the therapy. The pairing killed more cells and worked better in animals while staying tolerable. The authors propose testing the combination in patients.

Catalog record

CREATORMarco Ranzani, Alessandro Cicconi, Guillermo Sastre-Moreno, Asmita Thapa, Elise Simon, Josefine Reber, Joseph Barlow, Marie Laure Boursier, Aurora Cerutti, Luisa Deberle, Luigi Del Pozzo, Elias Elinati, Lerin Geo, Vera Grinkevich, Charlene Hartnagel, Sravanth K. Hindupur, Katjusa Koler, Suraj Menon, Joana Neves, Barbara Schacher, Nan Shao, Eeson Rajendra, Markus Reschke, Tobias Schmelzle, Graeme C. M. Smith, Helen M. R. Robinson, Marta Cortes-Cros
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53324
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13633323

Browse the full library · About the Tower of Babel